Sapitinib (AZD8931)

InformationSapitinib (AZD8931) is a reversible, ATP competitive inhibitor ofEGFR,ErbB2andErbB3withIC50of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and FlIn vitroAZD8931 shows different potency to NSCLC and SCCHN cell lines. AZD8931 has high sensitivity to PC-9 cells (EGFR activating mutation) with GI50 of 0.1 nM and low activity to NCI-1437 cells with GI50 above 10 μM. AZD8931 exhibits more potency against phospho-EGFR, phospho-erbB2 and phospho-erbB3 than either lapatinib or gefitinib in PE/CA-PJ41, PE/CA-PJ49, DOK and FaDu cells.In vivoAZD8931 reveals antitumor activity in BT474c, Calu-3, LoVo, FaDu and PC-9 xenografts. AZD8931 could reduce p-Akt, Ki67 expression and p-ERK in BT474c xenografts following acute treatment. AZD8931 also causes induction of the M30 apoptosis marker. Furthermore, AZD8931 shows greater proapoptotic effect compared with gefitinib and lapatinib in LoVo xenografts.Cell Datacell lines：COS-7 cells expressing human AT1 receptorsConcentrations：0.001-10 μMIncubation Time：96 hoursPowder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C23H25ClFN5O3 Molecular Weight: 473.93

UPC:

51112003

Condition:

New

Weight:

0.85 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

S408729-1ml

CAS:

848942-61-0

Product Size:

1ml